Listing of existing shares on Euronext Brussels & Amsterdam
May 17 2016 - 1:10AM
Galapagos (Euronext & NASDAQ: GLPG) announces that, following
the approval of a listing prospectus by the Belgian Financial
Services and Markets Authority, the 6,760,701 shares subscribed to
by Gilead on 19 January 2016 have been admitted to
trading on Euronext Brussels and Amsterdam today. A copy of the
listing prospectus is available on our website at www.glpg.com.
About Galapagos Galapagos (Euronext & NASDAQ: GLPG)
is a clinical-stage biotechnology company specialized in the
discovery and development of small molecule medicines with novel
modes of action. Our maturing pipeline comprises Phase 2, Phase 1,
pre-clinical and discovery studies in cystic fibrosis,
inflammation, fibrosis, osteoarthritis and other indications. We
have discovered and developed filgotinib: in collaboration with
Gilead we aim to bring this JAK1-selective inhibitor for
inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel
medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 440
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Contacts
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn
Fox |
VP IR
& Corporate Communications |
Director
Communications +31 6 53 591 999 |
+1 781
460 1784 Paul van der Horst Director IR & Business Development
+31 6 53 725 199 |
communications@glpg.com
|
ir@glpg.com |
|
Forward-looking statements This release may
contain forward-looking statements, all of which involve certain
risks and uncertainties. These statements are often, but not
always, made through the use of words or phrases such as
"anticipates," "believes," "continues," "could," "estimates,"
"expects," "intends," "may," "plans," "seeks," "stands to," "we
believe," "will," "we intend," as well as similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition and liquidity, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent
with such forward-looking statements, they may not be predictive of
results or developments in future periods. Among the factors that
may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements
(including that data from Galapagos' ongoing clinical research
programs may not support registration or further development of its
product candidates due to safety, efficacy or other reasons),
Galapagos' reliance on collaborations with third parties, and
estimating the commercial potential of Galapagos' product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in Galapagos' Securities
and Exchange Commission (SEC) filings and reports, including in
Galapagos' most recent annual report on form 20-F filed with the
SEC and subsequent filings and reports filed by Galapagos with the
SEC. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking
statements, unless specifically required by law or regulation.
Listing of existing shares on Euronext
http://hugin.info/133350/R/2013013/745900.pdf
HUG#2013013
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024